Abstract
We have previously shown the neuroprotective effect of atypical antipsychotic agents by experimental cerebral ischemia. However the impact of their high dose related side effects on their low dosage related neuroprotectivity is still unknown.We evaluated the possible neuroprotective effects of high dose olanzapine (10mg/kg) treatment on ischemic brain injury 24 hr after permanent cerebral ischemia. Olanzapine showed neither a neuroprotective nor a neurotoxic effect after focal cerebral ischemia. This finding could suggest that dose related side effect of olanzapine could involve a restriction of its neuroprotective effect unlike lower doses that have been reported to have neuroprotective effect.
Keywords: Stroke, atypical antipsychotics, mood disorders
Medicinal Chemistry
Title: Olanzapine Does not Aggrevate Ischemic Neuronal Injury by Focal Cerebral Ischemia: A Dose Related Restriction of the Neuroprotective Effect?
Volume: 5 Issue: 3
Author(s): Burak Yulug and Ertugrul Kilic
Affiliation:
Keywords: Stroke, atypical antipsychotics, mood disorders
Abstract: We have previously shown the neuroprotective effect of atypical antipsychotic agents by experimental cerebral ischemia. However the impact of their high dose related side effects on their low dosage related neuroprotectivity is still unknown.We evaluated the possible neuroprotective effects of high dose olanzapine (10mg/kg) treatment on ischemic brain injury 24 hr after permanent cerebral ischemia. Olanzapine showed neither a neuroprotective nor a neurotoxic effect after focal cerebral ischemia. This finding could suggest that dose related side effect of olanzapine could involve a restriction of its neuroprotective effect unlike lower doses that have been reported to have neuroprotective effect.
Export Options
About this article
Cite this article as:
Yulug Burak and Kilic Ertugrul, Olanzapine Does not Aggrevate Ischemic Neuronal Injury by Focal Cerebral Ischemia: A Dose Related Restriction of the Neuroprotective Effect?, Medicinal Chemistry 2009; 5 (3) . https://dx.doi.org/10.2174/157340609788185864
DOI https://dx.doi.org/10.2174/157340609788185864 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Regulation of Innate Immune Responses in the Central Nervous System
CNS & Neurological Disorders - Drug Targets Withdrawn: Mesenchymal Stem Cell-derived Exosomes for Treatment of Ischemic Stroke
Current Stem Cell Research & Therapy Alzheimer’s Disease and the Early Signs of Age-Related Macular Degeneration
Current Alzheimer Research EPO Relies upon Novel Signaling of Wnt1 that Requires Akt1, FoxO3a,GSK-3β, and β-Catenin to Foster Vascular Integrity during Experimental Diabetes
Current Neurovascular Research Responses of Glial Cells to Stress and Glucocorticoids
Current Immunology Reviews (Discontinued) Adult Neurogenesis and Parkinsons Disease
CNS & Neurological Disorders - Drug Targets Cell and Gene Therapies for Refractory Epilepsy
Current Neuropharmacology Laminin and its Related Peptides for the Treatment of Alzheimers Disease
Current Medicinal Chemistry - Central Nervous System Agents Advances in Extracorporeal Detoxification by MARS Dialysis in Patients with Liver Failure
Current Medicinal Chemistry Dasatinib: An Anti-Tumour Agent via Src Inhibition
Current Drug Targets Natriuretic Peptides in Heart Failure and Post-Myocardial Infarction
Current Hypertension Reviews Role of PPAR in Cardiovascular Diseases
Recent Patents on Cardiovascular Drug Discovery Biologics: An Update and Challenge of Their Pharmacokinetics
Current Drug Metabolism Functional Switch From Pro-Neurotrophins to Mature Neurotrophins
Current Protein & Peptide Science Lipid Modulation of Intravascular and Cellular Sodium Handling:Mechanistic Insights and Potential Clinical Implications
Current Vascular Pharmacology Microglial Activation in Alzheimers Disease
Current Alzheimer Research Evolving Drug Delivery Strategies to Overcome the Blood Brain Barrier
Current Pharmaceutical Design Safety of Vascular Endothelial and Hepatocyte Growth Factor Gene Therapy in Patients with Critical Limb Ischemia
Current Neurovascular Research Treatment Options in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders
Current Pharmaceutical Design Editorial (Thematic Issue: Towards New Approaches in Alzheimer’s Research and Alzheimer’s Disease)
Current Alzheimer Research